- Home
- THRD vs NPCE Comparison
THRD vs NPCE Comparison
Compare THRD & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- NPCE
- Stock Information
- Founded
- THRD 2019
- NPCE 1997
- Country
- THRD United States
- NPCE United States
- Employees
- THRD N/A
- NPCE N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- NPCE Medical Specialities
- Sector
- THRD Health Care
- NPCE Health Care
- Exchange
- THRD Nasdaq
- NPCE Nasdaq
- Market Cap
- THRD 335.2M
- NPCE 355.5M
- IPO Year
- THRD 2022
- NPCE 2021
- Fundamental
- Price
- THRD $6.00
- NPCE $13.06
- Analyst Decision
- THRD Strong Buy
- NPCE Buy
- Analyst Count
- THRD 3
- NPCE 7
- Target Price
- THRD $20.33
- NPCE $16.00
- AVG Volume (30 Days)
- THRD 248.2K
- NPCE 85.8K
- Earning Date
- THRD 11-07-2024
- NPCE 03-04-2025
- Dividend Yield
- THRD N/A
- NPCE N/A
- EPS Growth
- THRD N/A
- NPCE N/A
- EPS
- THRD N/A
- NPCE N/A
- Revenue
- THRD N/A
- NPCE $76,452,000.00
- Revenue This Year
- THRD N/A
- NPCE $23.82
- Revenue Next Year
- THRD N/A
- NPCE $14.31
- P/E Ratio
- THRD N/A
- NPCE N/A
- Revenue Growth
- THRD N/A
- NPCE 27.00
- 52 Week Low
- THRD $5.60
- NPCE $5.45
- 52 Week High
- THRD $16.94
- NPCE $18.15
- Technical
- Relative Strength Index (RSI)
- THRD 23.75
- NPCE 68.23
- Support Level
- THRD $5.60
- NPCE $11.37
- Resistance Level
- THRD $11.78
- NPCE $12.65
- Average True Range (ATR)
- THRD 0.89
- NPCE 0.98
- MACD
- THRD -0.43
- NPCE 0.01
- Stochastic Oscillator
- THRD 6.50
- NPCE 78.74
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.